SCHEMBL11920149

SCHEMBL11920149

N/N=C(\Nc1ccccc1Cl)c1ccncc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
GAA P10253 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.45
TYK2 P29597 1/20 0.43
LMNA P02545 3/20 0.42
MAPT P10636 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
MCL1 Q07820 1/20 0.42
NAMPT P43490 1/20 0.41
HTT P42858 2/20 0.41
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
CYP1A2 P05177 1/20 0.41
RAB9A P51151 3/20 0.40
MEN1 O00255 2/20 0.40
NPC1 O15118 2/20 0.40
KMT2A Q03164 2/20 0.40
MIF P14174 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9901536 1.00 POLB (0.51) POLBGAASMN1; SMN2TYK2LMNA
SCHEMBL27359514 0.80 GRM4 (0.52) POLBGAASMN1; SMN2LMNAMAPT
SCHEMBL9901891 0.80 GRM4 (0.52) POLBGAASMN1; SMN2LMNAMAPT
SCHEMBL9902869 0.76 GAA (0.71) POLBGAATYK2LMNAALDH1A1
SCHEMBL11920151 0.76 GAA (0.67) POLBGAASMN1; SMN2TYK2LMNA
SCHEMBL20385172 0.72 CYP1A2 (0.50) POLBLMNAMAPTKDM4EALDH1A1
SCHEMBL9901622 0.72 RAB9A (0.51) SMN1; SMN2LMNAMAPTKDM4EALDH1A1
SCHEMBL9901532 0.69 ALDH1A1 (0.47) POLBGAASMN1; SMN2TYK2LMNA
SCHEMBL9901529 0.69 ALDH1A1 (0.47) POLBGAASMN1; SMN2TYK2LMNA
SCHEMBL20385087 0.68 CYP1A2 (0.42) LMNAMAPTKDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
WO-2010139966-A1 AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS OSLO UNIVERSITY HOSPITAL HF (NO) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 POLB 2719/4885GAA 2285/4885SMN1; SMN2 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.